Abbott Has Lost More Than 10% This Year, and $1,000 From Five Years Ago Is Worth Less Than $950
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Abbott Laboratories (NYSE:ABT | ABT Price Prediction) has fallen 17.79% in 2026, slipping from $125.29 at the end of 2025 to $103.00. Over that same stretch, the S&P 500 is up 1.16%. For a blue-chip healthcare name, five years of going nowhere is a painful result.
A $21 Billion Deal Couldn’t Stop the Slide
Abbott spent the past five years working off its pandemic testing boom and leaning on FreeStyle Libre glucose monitors and electrophysiology for growth. In 2026, it went bigger, closing the $21 billion Exact Sciences acquisition on March 23, 2026, to add Cologuard cancer screening.
Investors kept selling anyway, and shares fell 10.04% on the Q4 2025 report and 6% on Q1 results. In October, management lowered its full-year sales outlook, citing established pharmaceuticals and diabetes. CGM growth cooled to 8%[1] amid international pricing pressure. Abbott also announced plans to spin off its nutrition business by the end of next year[1].
Your $1,000 Shrank to $899.80 Over Five Years
1-Year Return
- Initial Investment: $1,000
- Current Value: $853.80
- Total Return: -14.62%
- S&P 500 (same period): $1,057.10 (5.71%)
5-Year Return
- Initial Investment: $1,000
- Current Value: $899.80
- Total Return: -10.02%
- Annualized Return: -2.09%
- S&P 500 (same period): $1,471.20 (47.12%)
10-Year Return
- Initial Investment: $1,000
- Current Value: $3,271.50
- Total Return: 227.15%
- Annualized Return: 12.58%
- S&P 500 (same period): $3,127.30 (212.73%)
Entry timing shaped the outcome: a buyer in 2016 still edges out the index, but every bit of that lead was built in the first half of the decade. Anyone who bought in the past half-decade has trailed the market badly since.
Dividends cushioned the ride as the quarterly payout rose from $0.45 in 2021 to $0.63 in 2026, extending a streak to 54 consecutive years of increases (we ranked ten names with 50-plus-year streaks by valuation in a free Dividend Kings report). Income investors got paid to wait, even as the share price floated lower.
What Could Revive Abbott’s Growth Story
The stock has more upside if CGM growth reaccelerates and the nutrition spin leaves a thinner, faster company. The outlook weakens if diabetes stays stuck in low single figures while Cologuard has to carry the growth story alone.
On the optimistic side, management expects the remaining company’s gross margin to rise by more than 200 basis points[1] without nutrition. Libre Duo also launches in the U.S. in December[1]. At a forward P/E of 18, the valuation already prices in significant disappointment.
On the bear side, CEO Robert Ford said diabetes growth should stay in the low to mid-single-digit range[1] for the next few quarters. He also does not expect Medicare reimbursement for type 2 patients who don’t use insulin anytime soon. Abbott has already said it will set conservative initial 2027 guidance.
Investors tracking the stock will look for one clean quarter of Libre reacceleration as a key signal, while the 2.41% yield provides income for existing shareholders in the meantime.
Contact [email protected] for any questions or corrections.







